Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Chikungunya virus envelope glycoprotein E1 is a class II fusion protein embedded in the virion lipid bilayer, forming heterodimers with E2 (derived from p62 precursor after furin cleavage) that trimerize into 80 icosahedral spikes (T=4 symmetry). It drives low pH-dependent membrane fusion during endosomal entry by exposing its fusion loop (residues 83-100 in domain II), inserting into the host membrane, and trimerizing. E1 also contributes to virus attachment by modulating E1-E2 interactions and binding to glycosaminoglycans like heparin/heparan sulfate, influences receptor interactions (e.g., Mxra8 via E2 changes), stabilizes the glycoprotein lattice through E1-E1 interspike contacts, and supports particle assembly, egress, and immunogenicity. Mutations (e.g., V156A, K211T, M88L, N20Y) alter E2 conformation, cell-type-specific infectivity, GAG binding, antibody neutralization, and pathogenesis in mice and insects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chikungunya virus envelope glycoprotein E1 (E1).